NCL’s first fund is based at Discovery Park and invests primarily in a diverse range of biotech and environmental technologies:

Emerging clinical stage biotechnology business developing a revolutionary treatment for asthma


Specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health


Clinical stage Immuno-Oncology business with pipeline of innovate cell therapies


Biotech company developing novel immunotherapies to combat cancer and infectious disease


The World’s first real time airborne asbestos Alert


Creating beautiful office furniture from waste cardboard


Clean low cost drying technologies


Principal advisor to seed round


NCL also manage some existing equity investments of one of our main local authority investors:

Sold to Sienna Biopharmaceuticals – 2016


Medical grade iPad case


Molecular detection technology providing unprecedented levels of sensitivity


Accessible digital health records for clinicians and patients


Real time sentiment data analytics for the financial markets


Non-invasive skin cancer diagnostic


Targeted venom discovery arrays for pharma and cosmetic use


Efficient and low emission vehicle exhaust system


Pharmaceutical consultancy and drug discovery platform


Compact and wearable cough monitor for asthma and COPD


NCL have recently launched their new Life Science fund.  Details can be provided by the company upon request.